Evidence map›Paper›PMID 35494477›Full record

ArticleRSC advances2020

Development of multiple reaction monitoring assay for quantification of carnosine in human plasma.

Vaibhav Kumar Pandya, Babasaheb Sonwane, Rajeshwari Rathore, A G Unnikrishnan, Sangaralingam Kumaran, Mahesh J Kulkarni

Open access · goldAbstract read
In one paragraph

Article in RSC advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Vaibhav Kumar PandyaProteomics Facility, Biochemical Sciences Division, CSIR-National Chemical Laboratory Pune-411008 India mj.kulkarni@ncl.res.in +912025902541.
Babasaheb SonwaneProteomics Facility, Biochemical Sciences Division, CSIR-National Chemical Laboratory Pune-411008 India mj.kulkarni@ncl.res.in +912025902541.
Rajeshwari RathoreProteomics Facility, Biochemical Sciences Division, CSIR-National Chemical Laboratory Pune-411008 India mj.kulkarni@ncl.res.in +912025902541.
A G UnnikrishnanChellaram Diabetes Institute Pune-411008 India.
Sangaralingam KumaranCSIR-Institute of Microbial Technology Chandigarh-160036 India.
Mahesh J KulkarniProteomics Facility, Biochemical Sciences Division, CSIR-National Chemical Laboratory Pune-411008 India mj.kulkarni@ncl.res.in +912025902541.ORCID https://orcid.org/0000-0003-3932-9092
Biochemical Society · GBChandigarh University · INChellaram Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carnosine, a histidine containing dipeptide, exerts beneficial effects by scavenging reactive carbonyl compounds (RCCs) that are implicated in pathogenesis of diabetes. However, the reduced carnosine levels may aggravate the severity of diabetes. The precise quantification of carnosine levels may serve as an indicator of pathophysiological state of diabetes. Therefore, we have developed a highly sensitive targeted multiple reaction monitoring (MRM) method for quantification of carnosine in human plasma samples. Various mass spectrometry parameters such as ionization of precursor, fragment abundance and stability, collision energy, tube lens offset voltage were optimized to develop a sensitive and robust assay. Using the optimized MRM assay, the lower limit of detection (LOD) and limit of quantification (LOQ) for carnosine were found to be 0.4 nM and 1.0 nM respectively. Standard curves were constructed ranging from 1.0 nM to 15.0 μM and the levels of carnosine in mice and human plasma were determined. Further, the MRM assay was extended to study carnosine hydrolyzing activity of human carnosinases, the serum carnosinase (CN1) and the cytosolic carnosinase (CN2). CN1 showed three folds higher activity than CN2. The MRM assay developed in this study is highly sensitive and can be used for basal plasma carnosine quantification, which can be developed as a novel marker for scavenging of RCCs in diabetes.

Identifiers

PMID35494477
PMCPMC9047520
OpenAlexW2997227566

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.